Anti-atherosclerotic effect of incretin receptor agonists

被引:2
|
作者
Wang, Xin [1 ]
Yang, Xin [1 ]
Qi, Xiaoyan [2 ,3 ]
Fan, Gang [3 ,4 ]
Zhou, Lingzhi [3 ,5 ]
Peng, Zhengliang [6 ]
Yang, Jing [1 ,2 ,3 ]
机构
[1] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Metab & Endocrinol, Hengyang, Hunan, Peoples R China
[2] Shenzhen Nanshan Peoples Hosp, Dept Metab & Endocrinol, Shenzhen, Guangdong, Peoples R China
[3] Shenzhen Univ Hlth Sci Ctr, Affiliated Hosp 6, Shenzhen, Guangdong, Peoples R China
[4] Shenzhen Nanshan Peoples Hosp, Dept Urol, Shenzhen, Guangdong, Peoples R China
[5] Shenzhen Nanshan Peoples Hosp, Dept Pediat, Shenzhen, Guangdong, Peoples R China
[6] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Emergency, Hengyang, Hunan, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
incretin receptor agonists; type 2 diabetes mellitus; cardiovascular disease; atherosclerosis; vasculoprotective effects; DEPENDENT INSULINOTROPIC POLYPEPTIDE; PEPTIDE-1 ANALOG LIRAGLUTIDE; ENDOTHELIAL-CELL DYSFUNCTION; ONCE-WEEKLY SEMAGLUTIDE; SMOOTH-MUSCLE-CELLS; END-PRODUCTS AGES; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; ATHEROSCLEROTIC LESIONS; VASCULAR ENDOTHELIUM;
D O I
10.3389/fendo.2024.1463547
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Incretin receptor agonists (IRAs), primarily composed of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide receptor agonists (GIPRAs), work by mimicking the actions of the endogenous incretin hormones in the body. GLP-1RAs have been approved for use as monotherapy and in combination with GIPRAs for the management of type 2 diabetes mellitus (T2DM). In addition to their role in glucose regulation, IRAs have demonstrated various benefits such as cardiovascular protection, obesity management, and regulation of bone turnover. Some studies have suggested that IRAs not only aid in glycemic control but also exhibit anti-atherosclerotic effects. These agents have been shown to modulate lipid abnormalities, reduce blood pressure, and preserve the structural and functional integrity of the endothelium. Furthermore, IRAs have the ability to mitigate inflammation by inhibiting macrophage activation and promoting M2 polarization. Research has also indicated that IRAs can decrease macrophage foam cell formation and prevent vascular smooth muscle cell (VSMC) phenotype switching, which are pivotal in atheromatous plaque formation and stability. This review offers a comprehensive overview of the protective effects of IRAs in atherosclerotic disease, with a focus on their impact on atherogenesis.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
    Barbarawi, Mahmoud
    Aburahma, Ahmed
    Zayed, Yazan
    Osman, Mohammed
    Rashdan, Laith
    Swaid, Bakr
    Bachuwa, Ghassan
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2018, 8 (06): : 349 - 356
  • [2] Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril
    Fonseca, FAH
    Ihara, SSM
    Izar, MCO
    Silva, EP
    Kasinski, N
    Lopes, IEL
    Pinto, LESA
    Paiva, TB
    Tufik, S
    de Paola, AAV
    Carvalho, ACC
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (10) : 779 - 785
  • [3] Experimental study of the anti-atherosclerotic effect of demethylzeylasteral
    Huang, Ying
    Wang, Shaofeng
    Zhang, Chunya
    Xu, Zhiqing
    Shen, Jinghua
    Du, Xiaogang
    Zhang, Huanhua
    Zhang, Kangjian
    Zhang, Daifu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (06) : 2787 - 2792
  • [4] Anti-atherosclerotic effects by AT1 receptor blockade
    de Faire, U
    JOURNAL OF HYPERTENSION, 2003, 21 (02) : 259 - 260
  • [5] The potential anti-atherosclerotic effect of itraconazole a medical hypothesis
    Feily, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (08) : 552 - 553
  • [6] Bacterial butyrate mediates the anti-atherosclerotic effect of silybin
    Shen, Hao-Ran
    Wang, Zhi-Yu
    Shen, Zhen
    Liu, Tong-Tong
    Guo, Yun-Dan
    Gao, Tian-Le
    Guo, Hui-Hui
    Han, Yan-Xing
    Jiang, Jian-Dong
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 169
  • [7] Emerging Anti-Atherosclerotic Therapies
    Gluba-Brzozka, Anna
    Franczyk, Beata
    Rysz-Gorzynska, Magdalena
    Lawinski, Janusz
    Rysz, Jacek
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [8] Anti-atherosclerotic effect of cilostazol in ApoE knockout mice
    Takase, H
    Hashimoto, A
    Okutsu, R
    Hirose, Y
    Miyakoda, G
    Mori, T
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 188P - 188P
  • [9] Does the AT2-receptor mediate anti-atherosclerotic actions?
    Kintscher, U
    Unger, T
    JOURNAL OF HYPERTENSION, 2005, 23 (08) : 1469 - 1470
  • [10] Anti-atherosclerotic efficacy of olmesartan
    Miyazaki, M
    Takai, S
    JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (Suppl 2) : S7 - S12